A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
07/07/2021at 09:12

Amplifon expands Chinese presence in new joint venture

A novel Chinese collaboration increases the presence of hearing aid company Amplifon in the market in Southeast China.
Photo: Jens Dresling
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

The Italian retailer Amplifon, which is a customer of both Demant and GN Hearing, has taken a larger chunk of the Chinese retail market.

The firm has started a new joint venture company with a local partner, which Amplifon will own 51 percent of, the Italian firm revealed on Tuesday.

The joint venture will increase Amplifon's presence in the Zheijang province and Southeast China.

"This transaction represents another important step in our journey to build a leading position in the strategic Chinese market, which represents a sizeable medium-term opportunity given the estimated market size and its outstanding growth potential," says CEO Enrico Vita in a press release.

The transaction has already received all the regulatory clearances that are necessary from local authorities, according to Amplifon.

The Italian company is the world's largest retailer of hearing aids with a global market share of around 11 percent.

It has shops in 26 countries and around 9,000 audiologists in its employ.

FDA plans new sales channel for hearing aids in autumn 

Sale of hearing aids in the US exceeds 4 million devices for the first time 

Related articles:

  • FDA plans new sales channel for hearing aids in autumn

    For subscribers

  • Photo: PR / GN

    Sale of hearing aids in the US exceeds 4 million devices for the first time

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Lead Data Architect

  • Experienced Patent Counsel

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Head of International Sales

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

See all jobs

Jobs

  • Lead Data Architect

  • Experienced Patent Counsel

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Head of International Sales

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge